Usually, individuals start weight loss programs with uncertain expectations
Read about NCLs impact Building a stronger generation A grease fire flared up in Decklans kitchen
TRIUMPH-4 results and dosing insights The TRIUMPH-4 trial focused on adults with obesity and knee osteoarthritis
En casos excepcionales, los pacientes pueden sufrir pancreatitis
While tirzepatide is not designed or approved for autoimmune disease treatment, preliminary research has identified potential anti-inflammatory properties associated with GLP-1 receptor agonists as a drug class
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
